Diagnosis, Lung Cancer
Conditions
Keywords
Exosome, biomarker, lung cancer, diagnosis, prognosis, liquid biopsy
Brief summary
Lung cancer is a leading cause of cancer death worldwide. Early diagnosis is linked to a better prognosis. Further, surgical resection at the early stages of non-small cell lung cancer (NSCLC) results in markedly improved survival rates. Computed tomography (CT)- or bronchoscopy-guided needle biopsies are standard definitive diagnostic procedures for lung cancer and are used to obtain tissue for pathological examination. However, these procedures are invasive, difficult to repeat, expensive, and risk exposure to radiation. Conversely, liquid biopsies, such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs), are simple and less invasive procedures that can be repeated more frequently than tissue biopsies. This study is a retrospective blood sample obtained and prospectively comparative analysis of various biomarkers (cancer markers, and exosome markers) derived from peripheral blood and pulmonary venous blood from patients who underwent lung cancer surgery. And treatment monitoring using biomarkers compare with peripheral and pulmonary blood.
Interventions
DIAGNOSTIC_TESTfrozen blood plasma samples
Analysis of various biomarkers using frozen blood samples
Sponsors
Korea University Guro Hospital
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults with Korean nationality * Patients who did not receive neoadjuvant therapy before surgery * Patients not diagnosed with any other cancer before surgery * Patients who agreed to the consent form for a donation of human materials during surgery
Exclusion criteria
* Patients who do not meet the inclusion criteria
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparative analysis of cancer marker concentrations in a peripheral vein and primary lung cancer outflow pulmonary vein | 2020 ~ 2025 | 1. Comparative analysis of CEA and lung cancer-specific exosome marker concentrations in peripheral blood and pulmonary blood using ELISA assay 2. Characterization of exosomes using western blot, NTA, and TEM analysis |
| Diagnostic analysis of lung cancer-specific exosome marker concentrations in a peripheral vein and primary lung cancer outflow pulmonary vein | 2020 ~ 2025 | 1\) Evaluation of the clinical usefulness of lung cancer diagnosis using lung cancer-specific exosome markers in peripheral vein blood and primary lung cancer outflow pulmonary vein-derived blood. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of lung cancer treatment monitoring using lung cancer-specific exosome biomarkers | 2020 ~ 2025 | Clinical evaluation of recurrence or cancer metastasis after treatment in patients who underwent lung cancer surgery using lung cancer-specific exosome biomarkers according to blood sample location (peripheral vein blood and primary lung cancer outflow pulmonary vein derived blood) |
Countries
South Korea
Contacts
Primary ContactHyun Koo Kim, MD, PhD
Outcome results
None listed